Cargando…
Corroboration of Height Velocity Prediction Markers for rhGH With an Oral GH Secretagogue Treatment in Children With GHD
CONTEXT: Recombinant human growth hormone (rhGH) is approved for treatment of pediatric growth hormone deficiency (GHD), with greatest growth responses observed in those with severe GHD. Orally administered GH secretagogues (GHS) may be useful treatment in patients with moderate GHD. Distinguishing...
Autores principales: | Blum, Werner F, Bright, George M, Do, Minh-Ha T, McKew, John C, Chen, Haiying, Thorner, Michael O |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101276/ https://www.ncbi.nlm.nih.gov/pubmed/33982678 http://dx.doi.org/10.1210/jendso/bvab029 |
Ejemplares similares
-
Development of a Predictive Enrichment Marker for the Oral GH Secretagogue LUM-201 in Pediatric Growth Hormone Deficiency
por: Bright, George M, et al.
Publicado: (2021) -
Diagnosis of Idiopathic GHD in Children Based on Response to rhGH Treatment: The Importance of GH Provocative Tests and IGF-1
por: Felício, João Soares, et al.
Publicado: (2019) -
GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy
por: Savage, Martin O., et al.
Publicado: (2021) -
Noonan syndrome: rhGH treatment and
PTPN11
mutation
por: Wu, Xian, et al.
Publicado: (2023) -
LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency
por: Bright, George, et al.
Publicado: (2021)